Checkmate Or Stalemate? Valeant's Autumn From Investing Grace

In my final post, I looked at how the pharmaceutical as well as biotechnology businesses receive got diverged, peculiarly inward the final decade, as well as the implications for earnings, R&D as well as marketplace pricing of these companies. The pharmaceutical business, inward particular, faces a novel landscape amongst many companies even as well as so stuck amongst a work organisation model that does non piece of work inward delivering value, every bit growth eases as well as margins come upwardly nether pressure. It is no surprise thus that investors are looking for a drug fellowship amongst a novel work organisation model, as well as that may explicate the meteoric ascent of Valeant over the v years, making its recent collapse all the to a greater extent than shocking.

Valeant: The Rise

The best agency to illustrate Valeant's ascent inward the drug work organisation is describe its history inward numbers. The graph below looks at the fourth dimension line of revenues, operating income as well as internet income from 1993 to the the final twelve months ending inward September 2015:

As yous tin see, the inflection holler for is inward 2010, when Valeant went from a fellowship amongst small, slow-growing revenues into hyper speed, increasing revenues almost x plication betwixt 2010 as well as 2015. That increment inward revenues was accompanied past times increases inward operating income as well as internet income, albeit smaller inward proportional terms. The story of how Valeant was able to accelerate its growth has been widely told, but the numbers in ane lawsuit to a greater extent than tell it better.

Year	R&D	Acquisitions	R&D/Sales	Acquisitions/Sales
2005	$69.42	$-	7.40%	0.00%
2006	$77.80	$-	7.29%	0.00%
2007	$100.61	$-	11.94%	0.00%
2008	$69.81	$101.90	9.22%	13.46%
2009	$47.58	$-	5.80%	0.00%
2010	$67.91	$(308.98)	5.75%	-26.16%
2011	$65.69	$2,464.10	2.71%	101.51%
2012	$79.10	$3,485.30	2.27%	100.14%
2013	$156.80	$5,253.50	2.72%	91.12%
2014	$246.00	$1,102.60	2.98%	13.35%
LTM	$297.60	$14,123.20	2.98%	141.46%

The growth has been driven almost solely past times acquisitions, totaling $26.4 billion since 2010. Looking closer at the 23 acquisitions that Valeant has made since 2013, the fellowship has bought to a greater extent than someone businesses (18 out of the 23) than public, though a really large proportion of the total cost tin live accounted for amongst 2 acquisitions, ane of a populace fellowship (Salix for $12.5 billion) as well as ane of a someone work organisation (Bausch as well as Lomb for $8.7 billion. Valeant seems to receive got also paid for almost all of these acquisitions amongst cash, which raises the interesting follow upwardly inquiry of where they came upwardly amongst the cash. Again, the answer is inward the numbers, amongst the nautical chart below providing a breakdown of funding sources during the menstruation from 2011-2015, the peak menstruation for Valeant's acquisitions:

Source: Valeant Statement of Cash Flows

At to the lowest degree during this period, the marketplace liked the Valeant work organisation model of growth through acquisitions, as well as delivered its verdict past times pushing upwardly Valeant's marketplace capitalization as well as pricing multiples.

Valeant: The Fall

It is perchance because Valeant rose as well as so rapidly from its mid-cap condition to larn a star that its needlelike autumn has been as well as so shocking. The refuse started amongst a report, on Oct 19, on a courtroom filing inward California as well as picked upwardly steam when it was highlighted on Oct 21 past times Citron, an outfit that has long been critical of Valeant's accounting as well as operating practices. That written report claimed that Valeant had hidden a human relationship amongst shadowy chemist's shop entities as well as that it had used that human relationship to create its books. While around were quick to dismiss the written report every bit motivated past times Citron's brusk seat inward Valeant, the written report triggered scrutiny as well as Valeant's initial explanations satisfied no ane as well as the marketplace reacted accordingly:

Recognizing that it faced a major marketplace calamity, Valeant called a by this article inward the New York Times on Oct xiv (a few days earlier the brusk seller stories appeared inward the press). Now that Valeant is inward the populace eye, in that location is no agency that, fifty-fifty if this scandal passes, they tin provide to anonymity. Every drug toll increment for a Valeant drug volition live damage that goodwill does to both accounting statements as well as to expert sense, but the grade to which acquisition accounting has dingy upwardly the numbers at Valeant tin live captured past times looking at how they receive got taken over Valeant's financials inward the final 5 years:

Source: Valiant Financial Statements

Complexity: Valeant is a complex company, as well as its complexity is brought domicile past times both the volume of its annual filing (its last 10K from 2014 runs 537 pages) as well as its detail. That complexity comes partly from its strategy of growing through acquisitions as well as partly from the accounting for acquisitions, but around of it is clearly past times pattern (with the chemist's shop network as well as chess names for holdings).  Complexity is a double-edged sword, though, since inward expert times, investors assume the best well-nigh the things that they create non know or empathise as well as inward bad times, the fog created past times complexity creates a backlash. 

As amongst every scandal, I am certain that in that location volition live novel revelations as well as intelligence stories inward the calendar week ahead, around pointing to accounting problems, around to work organisation model failures as well as around to legal jeopardy. Even if Valeant emerges unscathed legally from this mess, I only don’t run into how they tin revert to their onetime work organisation model, as well as it is non clear to me that without it, they are anything to a greater extent than than a middling pharmaceutical company.

The Bottom Line

Does the imminent collapse of Valeant's heart as well as soul work organisation model imply that I grip amongst the brusk sellers who receive got used the Enron analogy to fence that this fellowship is a trounce worth nothing? No, as well as hither is why. Unlike Enron, a fellowship that used special operate entities as well as complex holdings to enshroud it debt as well as had no assets amongst tangible value at the fourth dimension of its troubles, Valeant chemist's shop holdings seem designed to a greater extent than for pricing ability than accounting sleight of manus as well as it owns assets that receive got existent value. Thus, fifty-fifty if Valeant's capacity to grow productively is removed tomorrow, it volition even as well as so receive got value every bit a going concern or every bit a collection of assets.

Going concern value

If Valeant is able to move far through its troubles intact, ane selection that is available to it is to larn a to a greater extent than conventional drug company, resting on R&D for (low) growth as well as making coin of its established products. To value Valeant inward this scenario, hither are the assumptions that I made:

• Base twelvemonth earnings: One of the positive effects of suspending an acquisition-driven strategy is that the expenses associated amongst acquisitions should also dissipate. Consequently, I added dorsum acquisition-related expenses (impairment of goodwill, acquisition charges) to operating income to larn to an adjusted operating income for the final twelve months. (Update: As around of yous receive got pointed out, the most twelve months of financials include only half-dozen months that include Salix as well as thus understate revenues as well as operating income. To remedy this, I require to select inward Salix's revenues as well as operating income from the last quarter of 2014 as well as the outset quarter of 2015 into my trailing numbers. Unfortunately, Salix did non file a first quarter earnings written report for this year, but hither is an approximation. In 2014, Salix generated $1.134 billion inward revenues but reported an operating loss. If yous assume that revenues come upwardly inward evenly over the twelvemonth as well as yous allow for the operating margin of 25.51% that Salix earned inward 2012 & 2013, yous larn revenues of well-nigh $567 1000000 and operating income of $145 1000000 for the missing quarters. Adding these to the trailing 12 calendar month numbers increases the value per portion to $77. H5N1 to a greater extent than optimistic take, where Valeant is able to earn its higher operating margin increases the value per portion to $81. The bottom line is that bringing inward Salix's bump to revenues as well as operating income, which is probable to create growth inward the side past times side twelve months, pushes upwardly value per portion but non past times plenty to alter my basic conclusion, which is that the stock is, at best, fairly valued.)
• Pricing backlash: I assumed that the contention over Valeant's drug pricing strategy volition termination inward curlicue backs of toll increases on around of its drugs, resulting inward a permanent drib of 10% inward earnings. (Update: Though this pose out seems to come upwardly out of left champaign (and it is subjective), it comes from lowering Valeant's pre-tax operating margin (prior to adjustments) of 28.3% towards that of other drug companies which is 25.5%; the drib of 2.8% is roughly the 10% drop. I am also assuming that in ane lawsuit the losses from prior acquisitions curlicue off, the taxation charge per unit of measurement volition motility upwardly to 20%, lower than the tax rate paid past times United States of America pharmaceutical companies, reflecting the company's Canadian base.)
• Low growth: If Valeant follows the measure pharmaceutical fellowship exercise of investing inward R&D as well as hoping for payoffs, its expected growth charge per unit of measurement volition drib to anemic levels (as suggested past times my final ship service on drug companies). I volition assume a 3% growth charge per unit of measurement inward earnings for the side past times side 10 years, good below the 20% posted past times Valeant over the final 5 years, but much of that growth was acquired. (Update: I know that management is forecasting 10% from organic growth. That may really good live truthful for side past times side year, every bit the Salix bump kicks in, but it is tough to sustain thereafter, amongst substantially increasing R&D.)
• R&D spending: I volition assume that Valeant volition receive got to invest inward R&D to hold this growth going, as well as inward my valuation, that investment volition reverberate the provide on working capital alphabetic quality of 15.25% that I receive got estimated for the fellowship (with the adjusted earnings).
• Cost of capital: Factoring inward both the expert side of Valeant's high debt ratio (the taxation effected cost of debt) as well as the bad side (higher cost of debt as well as equity) as well as the revenue exposure for Valeant (75% from developed markets, 25% from emerging markets), I guess a cost of working capital alphabetic quality of 7.52%.

The value that I guess for Valeant's equity, on a per portion basis, is $72.10, which is well-nigh 14% lower than the toll of $83.64 at the unopen of trading on Nov 10. Your views on Valeant may live really dissimilar from mine, as well as yous are welcome to exercise my spreadsheet to reverberate those views. The tabular array below summarizes the termination on value per portion of varying around of the assumptions:

Spreadsheet amongst valuation

Given my perspective on the company, as well as it is undoubtedly flawed, I don't run into Valeant every bit a significantly nether valued stock, inward spite of the toll drib over the final few weeks. I also don't run into it every bit bubble waiting to burst, a stock heading towards beingness worth nothing. For the moment, I mean value volition sit down on the sidelines as well as watch.

Sum of the parts

If this scandal has legs as well as non only lingers, but creates legal problems that taint Valeant every bit a corporation, in that location is a 2nd option. Just every bit Valeant’s ascent inward value was built on additions, yous could create a contrary strategy where value is generated past times subtraction. Thus, Valeant could sell itself slice past times slice (drugs as well as divisions) to the highest bidders, since each slice volition live worth to a greater extent than to an untainted buyer than it would live worth to Valeant. If this is the optimal path, it volition live interesting to run into if this squad that has built the fellowship upwardly over the final v years is willing to prepare aside hubris as well as intermission it downwards over the side past times side few years.

The Bottom Line
The Valeant story reinforces many of my existing biases against companies that grow primarily through acquisitions. I am willing to concede that this strategy tin pay off, if companies maintain discipline, but my sense amongst these companies is that they inevitably hitting a wall, either because they larn likewise large to rest disciplined or because the accounting creates likewise many opportunities to obfuscate as well as enshroud problems. While Valeant's attempt at creating a novel model for a drug work organisation may receive got failed, that does non brand the existing drug fellowship model a success either. The search has to move on!

YouTube Version

Blog posts inward this series

1. Divergence inward the Drug Business: Pharmaceuticals as well as Biotechnology
2. Checkmate or Stalemate? Valeant's Fall from Grace
3. Runaway Stories as well as Fairy Tale Endings: The Theranos Lesson
4. Value as well as Taxes: Breaking downwards the Pfizer- Allergan Deal

Data Attachments

1. Valeant 10K as well as 10Q
2. Valeant historical financials

Spreadsheets

1. Valeant Valuation inward Nov 2015

Faith, Feedback In Addition To Fear: Educate For The Valeant Test?

It is easier in addition to to a greater extent than fun to write close your winners than your losers, but it is also far to a greater extent than of import in addition to valuable to revisit your losers, where the even out has non played out the means you lot hoped it would. It is of import because it is piece of cake to lapse into denial in addition to concur on to your losers also long, non exclusively because you lot allow promise override skilful sense but also because the deed of selling is the ultimate admission that you lot made a mistake. It is valuable because you lot tin larn from these mistakes, if you lot tin laid aside pride in addition to preconceptions. So, it is alongside mixed feelings that I am returning to Valeant, a stock that I bought inwards May at $27, contending that it was worth $44, but where the marketplace has clearly had other ideas. 

Valeant: Revisiting the Past

I get-go wrote close Valeant but over a twelvemonth ago, when it was entering its nighttime phase, surrounded past times scandals, management intrigue in addition to operating problems. At the time, the stock had completed a real quick descent from marketplace star to occupation child, alongside its stock cost (market cap) dropping from $180 on Oct 1, 2015 to $80 on Nov 6, 2015. While at that spot were many inwards the value investing community, where it had been a long fourth dimension favorite, who felt that the marketplace had over reacted, my valuation of $77 left me but curt of the marketplace cost of $80 at the time. Over the adjacent few months, things went from bad to worse on almost every dimension. The management squad disintegrated, alongside many of the transcend players leaving inwards disgrace, in addition to the fellowship held dorsum on reporting its financials because it was having problem getting its books inwards order, never a skilful sign for investors. Testimony past times its transcend managers inwards front end of congressional commission shredded its corporate graphic symbol in addition to the fellowship faced legal challenges on multiple fronts. The market, non surprisingly, punished the stock equally the fellowship lurched from 1 crisis to but about other in addition to the stock cost dropped almost 75%:

In May 2016, I revisited the company, but subsequently it hired a novel CEO (Joseph Papa) in addition to Bill Ackman, a long-time activist investor inwards the company, decided to convey a to a greater extent than active utilization inwards the company. In revaluing the company, I noted that the missteps at the fellowship had hamstrung it to the betoken that it had during the catamenia of a twelvemonth made the transition from Valeant the Star to Valeant the Dog. The value that I estimated for the company, viewed equally such, was $43.56.

Download spreadsheet

In keeping alongside my topic that the value of a fellowship ever comes from an underlying story, it is worth beingness explicit close the even out that I was telling inwards this valuation. In May 2016, I viewed Valeant equally a mature pharmaceutical fellowship that would non exclusively never survive able to conk dorsum to its “acquisitive” days but was probable to lose solid set down to other pharmaceutical companies alongside ameliorate R&D models. Consequently, inwards my valuation, I assumed depression revenue growth in addition to lower margins in addition to a supply on upper-case missive of the alphabet that would converge on the cost of upper-case missive of the alphabet over time. My conclusion inwards May 2016 was to purchase Valeant at $27 because I felt that, notwithstanding the fog of missing information, management changes in addition to legal sanctions, the fellowship was a skilful buy. 

The Market Speaks

In the months since my purchase inwards May 2015, at that spot has been picayune to cheer close for Valeant investors. The stock had an extended swoon inwards belatedly June, recovered somewhat inwards August, earlier continuing its descent inwards the concluding 2 months, alongside iii possible explanations for the cost performance. One is that the debt overhang, alongside $30 billion addition inwards debt due, making it the most highly levered fellowship inwards the pharmaceutical business, creates marketplace spasms each fourth dimension worries close default resurface. In fact, every few weeks, another rumor surfaces of Valeant planning to sell a major chunk of itself (Bausch in addition to Lomb, Salix) to take away the debt burden. The minute is that the consolidation in addition to cleaning upwards for past times mistakes seems to survive taking a lot longer than expected, alongside revenues stagnating in addition to huge impairment charges pushing equity earnings into negative territory. The 3rd is that the legal risk that was triggered past times the events of concluding twelvemonth is showing no signs of abating, alongside the most recent intelligence story close indictment of Valeant executive, Gary Tanner, in addition to Philidor's Andrew Davenport  continuing the drip-drip of bad intelligence on this front.

For most of the concluding few months, equally the cost dropped, I involve hold been waiting for something to a greater extent than concrete to emerge, in addition to then that I could revalue the company. On Nov 8, Valeant filed its most recent earnings written report for the 3rd quarter, reporting that revenues were downward to a greater extent than for the 3rd quarter of 2016 in addition to larger losses than expected. It accompanied the written report alongside forrard guidance that suggested continued stagnation inwards revenues in addition to no quick profits recovery adjacent year, leading to a sell-off inwards the stock, pushing the cost downward to but below $14 on Nov 9. While I the reports is definitely non skilful news, I must confess that I did non encounter much inwards that written report that was game or even out changing. To encounter why, convey a aspect at the numbers contained inwards the most recent earnings report:

	2016, Q3	2015, Q3	Change	2016, Q1-3	2015, Q1-3	Change
Revenues	$2,480	$2,787	-11.02%	$7,271	$7,689	-5.44%
COGS	$658	$649	1.39%	$1,946	$1,855	4.91%
S,G &A	$661	$698	-5.30%	$2,145	$1,957	9.61%
R&D	$101	$102	-0.98%	$328	$239	37.24%
Amort & Impair, finite-lived intangible assets	$807	$679	18.85%	$2,389	$1,630	46.56%
Goodwill Impairment	$1,049	$-	NA	$1,049	$-	NA
Acquisiton Costs (all)	$67	$213	-63.93%	$131	$648	-65.06%
Operating Income	$(863)	$448	-292.63%	$(716)	$1,366	-152.42%
EBIT pre-acquisition costs	$(796)	$661	-220.42%	$(585)	$2,014	-129.05%
EBITDA	$1,060	$1,340	-20.90%	$2,853	$3,644	-21.71%
EBITDAR	$1,161	$1,442	-19.49%	$3,181	$3,883	-18.08%

It is truthful that the fellowship is delivering lower revenues than the revenues that I had forecast for the fellowship inwards May 2016 in addition to it is also truthful that the company’s profits margins are dropping. However, in addition to this may but survive my confirmation bias speaking, equally I aspect at the 3rd quarter numbers, it seems similar a pregnant portion the bad intelligence reported for the quarter reflects repentance for past times sins, non fresh transgressions. The fellowship has had to reply to its “price gouger” reputation past times showing restraint on farther cost increases (dampening revenue growth inwards its drug business) in addition to the losses inwards the 3rd quarter tin survive largely attributed to impairments of goodwill in addition to assets acquired during the go-go days. In the tabular array below, I intermission downward the driblet inwards operating income of $2.08 billion from the get-go 3 quarters of 2015 to the get-go 3 quarters of 2016 into it's element parts: 

	Effect on operating Income	% Effect
Declining Revenues	$(317)	15.27%
Change inwards Gross Margin	$(192)	9.24%
Change inwards SG&A	$(188)	9.05%
Change inwards R&D	$(89)	4.29%
Change inwards Acquisition Costs	$517	-24.89%
Change inwards Amortization (Assets + Goodwill)	$(1,808)	87.05%
Change inwards Operating Income, , First 3Q 2016 vs First 3Q 2015	$(2,077)	100.00%

The numbers advise that almost 87% of the pass upwards inwards operating income tin survive traced to amortization either of finite lived assets or goodwill, though at that spot has been deterioration inwards the occupation organisation model equally manifested inwards the pass upwards inwards sales in addition to gross margins. It is for this argue that the outcome this earnings written report has had on my “Valeant equally Dog” even out is muted, largely because the even out was non an uplifting 1 inwards the get-go place. My updated version of the even out is that Valeant is non that unlike from my one-time 1 (of irksome growth in addition to lower margins) alongside tweaks for an upfront adjustment catamenia where revenues are apartment in addition to margins worse than the past, equally the fellowship continues to slow pose its past times behind it. The value per part that I acquire alongside this even out is $32.50 in addition to the film is below:

Download spreadsheet

On Nov 8, 2016, alongside the stock cost at close $15, it was the biggest loser inwards my portfolio but if I trust my ain updated assessment of value of Valiant, it is at nowadays to a greater extent than undervalued (on a pct basis) than it was inwards May 2016. 

Faith in addition to Feedback

In both my valuation in addition to investments classes, I pass a pregnant amount of fourth dimension talking close organized faith in addition to feedback in addition to how they touching investing.

1. Faith: As an investor, you lot are acting on organized faith when you lot invest, organized faith inwards your assessment of value in addition to organized faith that the marketplace cost volition displace towards that value. If you lot involve hold no organized faith inwards your value, you lot volition abide by yourself constantly revisiting your valuation, if the marketplace moves inwards the incorrect management (the 1 that you lot did non predict) in addition to tweaking your numbers until your value converges on the price. If you lot involve hold no organized faith inwards markets, you lot volition non involve hold the tum to remain alongside your seat if the marketplace moves against you. 
2. Feedback: As an investor, you lot involve hold to survive opened upwards to feedback, i.e., involve hold that your even out (and valuation) are incorrect in addition to that marketplace movements inwards the incorrect management are a signal that you lot should survive revisiting your valuation. 

I sentiment my investing challenge equally maintaining a residual betwixt organized faith in addition to feedback since also much of 1 at the expense of the other tin survive dangerous. Faith without feedback tin atomic number 82 to doubling downward or tripling downward on your initial investment bet, blind to both novel data in addition to your ain oversights, in addition to that righteous pathway tin atomic number 82 to investment hell. Feedback without organized faith volition crusade an endless loop where marketplace cost changes atomic number 82 you lot to revisit in addition to modify your value in addition to your belongings catamenia volition survive measured inwards days in addition to weeks instead of months or years.  Stocks similar Valeant are an acid exam of my balancing act. There is a business office of me that is telling me that it is fourth dimension to head to the market, convey my losses in addition to sell the stock. However, doing that would survive a forthwith contradiction of my investment philosophy in addition to I am non quite gear upwards to abandon it yet. The minute is to avoid all nurture of the stock in addition to promise that the marketplace corrects on its own, but denial is neither organized faith nor feedback. The 3rd is to involve hold the fact that I did underestimate how long it would convey Valeant to pose its past times behind it in addition to to revalue the fellowship alongside my updated even out in addition to that is what I tried to do. That credence of feedback, though, has to survive accompanied past times an affirmation of faith; since it led me to purchase the stock at $27, when my estimated value was $43 inwards May 2016, it should atomic number 82 me to purchase fifty-fifty to a greater extent than at $15, alongside my estimated value at $32.50. So, I doubled my Valeant holdings, good aware of the many dangers that I face: that the operating pass upwards that you lot saw inwards the 3rd quarter of 2016 volition conk on inwards the hereafter years, that the debt charge volition acquire to a greater extent than painful if involvement rates ascent in addition to that the recent indictments of executives volition give away the theater to to a greater extent than legal jeopardy. If the essence of involve a chance is best captured alongside the Chinese symbol for crisis, which is a combination of the symbols for danger in addition to opportunity, Valeant would survive a perfect instance of how you lot cannot involve hold 1 without the other!

YouTube Video


Attachments

1. Valeant - Valuation inwards Nov 2016

A Valeant Update: Damaged Goods Or Deeply Discounted Drug Company?

Rats larn a bad rap for fleeing sinking ships. After all, given that survival is the strongest evolutionary impulse together with that rats are non high upwardly inwards the nutrient chain, why would they not? That idiom, unfortunately, is what came to quest heed equally I took some other human face at Valeant, the vessel inwards my investment portfolio that most closely resembles a sinking ship. This is a stock that I had trivial involvement in, during its glory days equally the ultimate value investing play, but that I took start a human face at, afterwards its acute autumn from grace inwards Nov 2015. While I stayed away from it then, I bought it inwards May 2016 afterwards it had dropped some other 60% together with I institute it inexpensive plenty to add together to my portfolio. I thence compounded my losses when I doubled my asset inwards Oct 2016, arguing that land it was, at best, an indifferently managed companionship inwards a pitiful business, it was nether priced at $14 . With the stock trading at less than $12 (and downwards to $10.50, equally I write this post) together with its biggest investor/promoter abandoning it, in that place is no means that I tin avert my eyes whatever longer from this develop wreck. So, hither I go!

Valeant: H5N1 Short (and Personal) History

I won't bore you lot past times repeating (for a 3rd time) the story of Valeant's autumn from investment grace, which happened amongst stunning speed inwards 2015, equally it went from value investing favorite to untouchable, inwards the affair of months. My start post, from Nov 2015, examined the companionship inwards the aftermath of the fall, equally it was touted equally a contrarian bet, trading at unopen to $90, downwards to a greater extent than than 50% inwards a few months. My belief thence was that the company's line of piece of job organisation model, built on acquisitions, debt together with drug repricing was broken together with that the company, if it became a to a greater extent than conventional drug line of piece of job organisation company, amongst depression growth driven past times R&D, was worth $73 per share. I revisited Valeant inwards Apr 2016, afterwards the companionship had gone through a serial of additional setbacks, amongst many of its wounds self inflicted together with reflecting either accounting or administration misplays. At the time, amongst the updated data I had together with staying amongst my story of Valeant transitioning to a tedious drug company, amongst less attractive margins, I estimated a value per portion of $44, to a higher house the stock toll of $33 at the time. I bought my start batch of shares. In the months that followed, Valeant's woes continued, both inwards terms of operations together with stock price. After it announced a revenue driblet together with a reject inwards income inwards an lucre written report inwards Nov 2016, the stock hitting $14 together with I had no pick but to revisit it, amongst a fresh valuation. Adjusting the valuation for the novel numbers (and a to a greater extent than pessimistic receive got on how long it would receive got for the companionship to brand its means dorsum to beingness a conventional, R&D-driven pharmaceutical company, I valued the shares at $32.50. That may receive got been hopeful thinking but I added to my holdings at around $14/share.

Valeant: Updating the Numbers

Since that valuation, non much has gone good for the companionship together with its most recent lucre written report suggests that its transition dorsum to wellness is yet hitting roadblocks. While verbalize of imminent default seems to receive got subsided, in that place seems to live overwhelming pessimism on the company's operating  prospects, at to the lowest degree inwards the close term. In its most recent lucre report, Valeant reported farther deterioration inwards cardinal numbers:

	2016 10K	2015 10K	% Change
Revenues	$9,674.00	$10,442.00	-7.35%
Operating income or EBIT	$3,105.46	$4,550.38	-31.75%
Interest expense	$1,836.00	$1,563.00	17.47%
Book value of equity	$3,258.00	$6,029.00	-45.96%
Book value of debt	$29,852.00	$31,104.00	-4.03%

Much equally I would similar to believe that this reject is curt term together with that the stock volition come upwardly back, in that place is at nowadays a existent jeopardy that my story for Valeant, non an optimistic together with uplifting story to laid about with, is at nowadays broken. The company's growth strategy of acquiring other companies, using huge amounts of debt, raising prices on "under priced" drugs together with paying equally trivial inwards taxes equally possible were perchance legally defensible but they were ethically questionable together with may receive got damaged its reputation together with credibility thence thoroughly that it is at nowadays unable to larn dorsum to normalcy. This tin explicate why the companionship has had thence much problem non entirely inwards getting its operations dorsum on rails but also why it has been unable to pin to beingness a to a greater extent than traditional drug company. If researchers are leery almost working inwards your R&D department, if every toll increase you lot attempt to brand faces scrutiny together with force dorsum together with your credibility amongst markets is stone bottom, making the transition volition live tough to do. It tin also indirectly explicate why Valeant may live having problem selling some of its most lucrative assets, equally potential buyers appear wary of the corporate taint together with perchance receive got lingering doubts almost whether they tin trust Valeant's numbers.

In fact, the i argent lining that may emerge from this sense is that I at nowadays receive got the perfect representative to illustrate why beingness a line of piece of job organisation entity that violates the norms of practiced corporate demeanour (even if their actions legal) tin destroy value. At to the lowest degree inwards sectors similar wellness care, where the regime is a leading client together with predatory pricing tin Pb to to a greater extent than than merely populace shaming, the Valeant story should live a cautionary annotation for others inwards the sector who may live embarking on similar paths.

The Ackman Effect

You may uncovering it foreign that I would pass this much fourth dimension talking almost Valeant without mentioning what may appear to live the large story almost the stock, which is that Bill Ackman, long the company's biggest investor together with cheerleader together with for much of the in conclusion 2 years, a powerful board member, has admitted defeat, selling the shares that Pershing Square (his investment vehicle) has held inwards Valeant for almost $11 per share, representing a staggering loss of almost 90% on his investment. The reasons for my lack of response are similar to the ones that I voiced inwards this post, when I remained an Apple stockholders equally Carl Icahn sold Apple together with Warren Buffett bought the stock inwards Apr 2016. As an investor, I receive got to brand my ain judgments on whether a stock fits inwards my portfolio together with next others (no affair how much regard I receive got for them) is me-too-ism, destined for failure.  

Don't larn me wrong! I recall Bill Ackman, notwithstanding his Valeant setbacks, is an accomplished investor whose wins outnumber his losses together with when he takes a topographic point (long or short) inwards a stock, I volition banking company check it out. That said, I did non purchase Valeant because Ackman owned the stock together with I am non selling, merely because he sold. In fact, together with this may appear similar a stretch, it is possible that Ackman's presence inwards the companionship together with the potential veto ability that he mightiness receive got been exercising over large decisions may receive got conk to a greater extent than of an impediment than a assist equally the companionship tries to untangle itself from its past. I am non for certain how well-sourced these stories are, but in that place are some that suggest that it was Ackman who was the obstruction to a Salix sale in conclusion year.

Valeant: Three Outcomes

As I meet it, in that place are iii paths that Valeant tin take, going forward.

1. Going Concern: To value Valeant equally a going concern, I revisited my valuation from Nov 2016 together with made its pathway to stable drug companionship to a greater extent than rocky past times assuming that revenues would conk along to driblet 2% a twelvemonth together with margins volition rest depressed at 2016 levels for the side past times side five years together with that revenue growth volition rest anemic (3% a year) afterwards that, amongst a moderate improvement inwards margins. With those changes set inwards together with leaving the likelihood that the companionship volition non brand it at 10% (since the companionship has made some headway inwards reducing debt), the value per portion that I larn is $13.68. 

Download spreadsheet

To illustrate the uncertainty associated amongst this value estimate, I ran a simulation amongst my estimated distributions for revenue growth, margins together with cost of working capital missive of the alphabet together with arrived at the next distribution of values.

The simulation confirms the base of operations instance intrinsic valuation, insofar equally the median value of $13.31 is unopen to the toll at the fourth dimension of the valuation ($12) but it provides to a greater extent than data that may or may non contention the investment decision. There is a clear jeopardy that the equity could conk to zilch (about 12%), if the value dips below the outstanding debt ($29 billion). At the same time, in that place is pregnant upside, if the companionship tin uncovering a means to alter its trajectory together with conk a boring, depression growth drug company.

2. Acquisition Target: It is a sign of desperation when equally an investor, your best promise is that someone else volition larn your companionship together with pay a premium for it. I am afraid that the Valeant taint thence strong together with its construction thence opaque together with complex that real few acquirers volition desire to purchase the entire company. I meet trivial jeopardy of this bailing me out.

3. Sum of its parts, liquidated: It is truthful that Valeant has some valuable pieces inwards it, amongst Bausch & Lomb together with Salix beingness the biggest prices. While neither line of piece of job organisation has attracted equally much attending equally Valeant had hoped, in that place are 2 reasons why. The start is that Ackman, amongst pregnant losses on the stock together with a topographic point on the board, may receive got exercised some veto ability over whatever potential sales. The minute is that potential buyers may live scared away past times Valeant's history. One solution, at nowadays that Ackman is no longer at the company, is for Valeant to opened upwardly its books to potential acquirers together with sell its assets individually to the best possible buyers. Note that this liquidation value volition receive got to transcend $29 billion, the outstanding debt, for equity investors to generate whatever remaining cash.

There is i other macro concern that may brand Valeant's hereafter to a greater extent than thorny. As a companionship that pays a depression effective taxation charge per unit of measurement together with borrows lots of money, the proposed changes to the taxation police line (where the marginal taxation charge per unit of measurement is probable to live reduced together with the taxation savings from involvement expenses curbed), Valeant volition in all probability receive got to pay a much higher effective taxation charge per unit of measurement going forward, i argue why I receive got shifted to a 30% taxation charge per unit of measurement for the future.

The Bottom Line

Let's start amongst the tardily judgment. This was non an investment that I should receive got made together with much equally I would similar to blame macro forces, the company's administration together with Bill Ackman for my losses, this was my mistake. I was correct inwards my initial post inwards in conclusion that the company's one-time line of piece of job organisation model (of acquiring growth amongst borrowed coin together with repricing drugs) was broken but I clearly underestimated how much impairment that model has done to the company's reputation together with how much move it volition receive got for it to conk a boring, drug company. In fact, it is possible that the impairment is thence severe, the companionship volition non live able to brand the adjustments necessary to endure equally a going concern. 

So, at nowadays what? I cannot opposite the consequences of my master copy sin (of buying Valeant at $32) inwards Apr 2017 together with the secondary sin (of doubling down, when Valeant was trading at $14) past times selling now. The interrogation thence becomes a elementary one. Would I purchase Valeant at today's price? If the answer is yes, I should concord together with if the answer is no, I should fold. My intrinsic value per portion has dropped to merely to a higher house where the stock is trading at now, together with at this stage, my judgment is that, valued equally a going concern, it would live trading slightly nether value. In a foreign way, Bill Ackman's move out is what tipped the scales for me, since it volition plough over Valeant's management, if they are thence inclined, the capacity to brand the decisions that they may receive got been constrained from making before. In particular, if they recognize that this may live a clear instance where the companionship is worth to a greater extent than equally the amount of its liquidated parts than equally a going concern, in that place is yet a jeopardy that I could cut my losses on this investment. Note, though, that based on my numbers, I don't human face to brand my master copy investment (which averages out to $21/share) back. I am non happy almost that but sunk costs are sunk!

As I conk along to concord Valeant, I am also aware that I mightiness live committing i of investing's biggest sins, which is an aversion to admitting mistakes past times selling losers. My discounted cash menses valuations may live an after-the-fact rationalizing of something that I don't desire to do, i.e., sell a large loser. To counter this, I briefly considering selling the shares together with rebuying them dorsum immediately; that makes me acknowledge my error together with receive got my losses land restarting the investment procedure amongst a novel buy, but the "wash sales" dominion is an impediment to this cleansing exercise. The bottom line is that if I am asset on to Valeant, non for intrinsic value reasons (as I am trying to convince myself) but because I receive got an investing blind spot, I volition live in conclusion i to know!

YouTube Video

Previous Posts on Valeant

1. Checkmate or Stalemate: Valeant's Fall from Investing Grace (November 2015)
2. Valeant: Information Vacuums, Management Credibility together with Investment Value (April 2016)
3. Faith, Feedback together with Fear: The Valeant Test (November 2016)

Spreadsheets

1. Valeant Valuation: March 2017